2021
Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Huang KM, Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020168118. PMID: 33495337, PMCID: PMC7865186, DOI: 10.1073/pnas.2020168118.Peer-Reviewed Original ResearchConceptsOrganic cation transporter 3Cardiac injuryCardiovascular functionSide effectsTranslational relevanceCalcium-binding proteins S100A8Irreversible cardiac injuryCurrent preventative strategiesPotential translational relevanceCardiac damagePlasma levelsCardiac accumulationBreast cancerAntitumor effectsPharmacological targetingPreventative strategiesModest protectionProteins S100A8Critical transporterTransporter 3Pharmacological inhibitorsOverexpression modelIntervention strategiesDoxorubicinCardiotoxicity
2020
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia S, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal Of Clinical Investigation 2020, 130: 4601-4606. PMID: 32484793, PMCID: PMC7456253, DOI: 10.1172/jci136796.Peer-Reviewed Original ResearchConceptsOrganic cation transporter 2Peripheral neurotoxicityColorectal cancerOxaliplatin-induced peripheral neurotoxicityOxaliplatin-containing therapyOxaliplatin-induced neurotoxicitySatellite glial cellsOxaliplatin neurotoxicityChronic formCancer patientsGlial cellsPreclinical modelsPreventive strategiesMouse modelPharmacological approachesPharmacological targetingTranslational significanceNeurotoxicityTransporter 2PatientsUptake transportersCancerAnticancer drugsCandidate transportersSolute carriers